UAE, Japan pharma majors to set up manufacturing plant in Vizag
Hyderabad, April 26: Omnicare Drugs India Pvt Ltd, a 100 per cent subsidiary of the UAE's largest pharmaceutical manufacturer Neopharma LLC, and ASKA Pharmaceuticals Co, a top pharma brand in Japan, will jointly set up a manufacturing facility in Visakhapatnam.
The two companies on Thursday announced entering into an agreement to establish a joint venture (JV) in India for the purpose of manufacturing and marketing of pharmaceuticals to global market.
The focus of this state-of-the-art facility, which will come up by 2020 at the cost of Rs 350 crore, will be to manufacture oral solid dosage forms, oral liquids and topical preparations. It will have a peak capacity to manufacture 3 billion tablets a year, said a statement.
Neopharma and ASKA Pharma will be taking accreditation from all the major global health regulatory bodies.
The manufacturing plant under this JV agreement will be based at JN Pharma City in Andhra Pradesh's Visakhapatnam. The project will go on floor next month while the operations are likely to start by 2020.
The focus will be to manufacture products targeting chronic therapies in cardiovascular diseases, central nervous system and diabetes along with other drugs from key therapeutic classes targeting Japan and world market.
"The partnership will enable us to transfer skills and knowledge locally," said B.R. Shetty, Neopharma Founder and Chairman.
N. Suresh Kumar, Neopharma COO, said: "We are entering into a strategic relationship with ASKA Pharmaceuticals to accelerate growth in regulated markets of the US and the European Union and in the emerging markets Africa and Asia."
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Lenskart apologises after online backlash, releases new style guide welcoming religious symbols
New Delhi (PTI): Following massive online backlash over a purported internal grooming document, eyewear retailer Lenskart has issued a public apology and released a standardised 'In-Store Style Guide' that allows employees to wear religious and cultural symbols at work.
In a statement on X, the company said it is making its guidelines public and transparent to address the concerns of its customers and community.
The new policy "explicitly and unambiguously" welcomes all symbols of faith carried by team members, including the bindi, tilak, sindoor, kalawa, mangalsutra, kada, hijab, and turban.
"If any version of our workplace communication caused hurt or made any of our team members feel that their faith was unwelcome here, we are deeply sorry. That is not who Lenskart is, and it is not who we will ever be," the company said.
This comes following a controversy that erupted earlier this week when a document, alleged to be Lenskart's employee grooming policy, went viral on social media. Netizens pointed out that the policy restricted employees from wearing certain religious markers, particularly the bindi and tilak, sparking outrage and calls for a boycott.
Addressing the uproar a few days ago, Lenskart founder Peyush Bansal had stepped in to clarify that the viral document was an "outdated version" and did not reflect the company's current stance.
"I want to speak directly that this document does not reflect our present guidelines. Our policy has no restrictions on any form of religious expression, including bindi and tilak," Bansal had stated, apologising for the confusion and concern the situation had caused.
Building on Bansal's earlier clarification, Lenskart's latest statement emphasised the company's homegrown roots, noting that its 2,400-plus stores are run by people who bring their beliefs and traditions to work every day.
"Lenskart was built in Bharat, by Indians, for Indians... That is not something we will ever ask anyone to leave at the door," the statement read.
The retailer has now committed to ensuring that every future policy, training material, and communication carrying the Lenskart name will reflect inclusive values.
"We will do better. And we will keep earning your trust," the company said.
